SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: Role of IL-6 and GM-CSF

Cytokine

Volumn 23, Issue 1-2, 2003, Pages 1-14

  Kung Sutherland, May S ^a,b   Lipps, Stephanie G ^a   Patnaik, Nandita ^a   Gayo Fung, Leah M ^a,c   Khammungkune, Sak ^a,d   Xie, Weilin ^a   Brady, Helen A ^a   Barbosa, Miguel S ^a,e   Anderson, David W ^a,f   Stein, Bernd ^a  

^a CELGENE CORPORATION   (United States)

^b Celltech R and D Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d ISIS PHARMACEUTICALS   (United States)

^e Tanabe Research Laboratories   (United States)

^f Graceland University   (United States)

Author keywords

Co culture; GM CSF; IL 6; Osteoclast; SERMs

Indexed keywords

7 HYDROXY 3 PHENYL 4 [4 (2 PIPERIDINOETHOXY)BENZYL] 2H CHROMEN 2 ONE; 7 HYDROXY 3 PHENYL 4 [[4 (2 PIPERIDINYLETHOXY)PHENYL]METHYL] 2H CHROMEN 2 ONE; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE METABOLISM; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 10744230569     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-4666(03)00179-0     Document Type: Article

References (63)

1. Marcus R. Post-menopausal osteoporosis. Best Pract Res Clin Obstet Gynaecol. 16:2002;309-327.
2. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA. 288:2002;872-881.
3. Stein B., Yang M. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ Mol Cell Biol. 15:1995;4971-4979.
4. Brady H., Desai S., Gayo-Fung L.M., Khammungkhune S., McKie J.A., O'Leary E., et al. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res. 62:2002;1439-1442.
5. Brady H., Doubleday M., Gayo-Fung L.M., Hickman M., Khammungkhune S., Kois A., et al. Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator. Mol Pharmacol. 61:2002;562-568.
6. Girasole G., Jilka R., Passeri G., Boswell S., Boder G., Williams D., et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 89:1992;883-891.
7. Jilka R., Hangoc G., Girasole G., Passeri G., Williams D., Abrams J., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 257:1992;88-91.
8. Passeri G., Girasole G., Jilka R., Manolagas S. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 133:1993;822-828.
9. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1994;1189-1196.
10. Galien R., Evans H., Garcia T. Involvement of CCAAT enhancer-binding protein and nuclear factor-kappa binding sites in IL-6 promoter inhibition by estrogen. Mol Endocrinol. 10:1996;713-722.
11. Ohsaki Y., Takahashi S., Scarcez T., Demulder A., Nishihara T., Williams R., et al. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology. 131:1992;2229-2234.
12. Reddy S., Takahashi S., Dallas M., Williams R., Neckers L., Roodman G. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res. 9:1994;753-757.
13. Devlin R., Reddy S., Savino R., Ciliberto G., Roodman G. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res. 13:1998;393-399.
14. Bismar H., Diel I., Ziegler R., Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab. 80:1995;3351-3355.
15. MacDonald B., Mundy G., Clark S., Wang E., Kuehl T., Stanley E., et al. Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long term bone marrow cultures. J Bone Miner Res. 1:1986;227-233.
16. Lorenzo J., Sousa S., Fonseca J., Hock J., Medlock E. Colony-stimulating factors regulate the development of multinucleated osteoclasts from recently replicated cells in vitro. J Clin Invest. 80:1987;160-164.
17. Kurihara N., Chenu C., Miller M., Civin C., Roodman G. Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology. 126:1990;2733-2741.
18. Shinar D., Sato M., Rodan G.A. The effect of hematopoietic growth factors on the generation of osteoclast-like cells in mouse bone marrow cultures. Endocrinology. 126:1990;1728-1735.
19. Al-Saffar N., Khwaja H., Kadoya Y., Revell P. Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants. Anat Pathol. 105:1996;628-639.
20. Clover J., Gowen M. Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of osteoblastic phenotype? Bone. 15:1994;585-591.
21. Okazaki R., Conover C., Harris S., Spelsburg T., Riggs B. Normal human osteoblast-like cells consistently express genes for insulin-like growth factors I and II but transformed human osteoblast cell lines do not. J Bone Miner Res. 10:1995;788-795.
22. Wong M., Rao L., Ly H., Hamilton L., Tong J., Sturtridge W., et al. Long-term effects of physiologic concentrations of dexamethasone on human bone-derived cells. J Bone Miner Res. 5:1990;803-813.
23. Hu T., Ferril S., Snider A.-M., Barbosa M. In vivo analysis of HPV E7 protein association with pRb, p107, and p130. Int J Oncol. 6:1995;167-174.
24. Harris H. The human alkaline phosphatase: what we know and what we don't know. Clin Chim Acta. 186:1989;133-150.
25. Kung Sutherland M., Rao L., Muzaffar S., Wylie J., Wong M., McBroom R., et al. Age-dependent expression of osteoblastic phenotypic markers in normal human osteoblastic cells cultured long term in the presence of dexamethasone. Osteoporos Int. 5:1995;335-343.
26. de Pollak C., Arnaud E., Renier D., Marie P.J. Age-related changes in bone formation, osteoblastic cell proliferation, and differentiation during postnatal osteogenesis in human calvaria. J Cell Biochem. 64:1997;128-139.
27. Yoneda T., Alsina M., Garcia J., Mundy G. Differentiation of HL-60 cells into cells with the osteoclast phenotype. Endocrinology. 129:1991;683-689.
28. Aoki H., Akiyama H., Hosoya H., Souda M., Morioku T., Marunouchi T. Transient expression of M-CSF is important for osteoclast-like cell differentiation in a monocytic leukemia cell line. J Cell Biochem. 64:1997;67-76.
29. Roodman G. Advances in bone biology: the osteoclast. Endocr Rev. 17:1996;308-332.
30. Nguyen H., Hoffman-Liebermann B., Liebermann D. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage. Cell. 72:1993;197-209.
31. Kassem M., Harris S., Spelsburg T., Riggs B. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. J Bone Miner Res. 11:1996;193-199.
32. Kung Sutherland M, Brady H, Gayo-Fung LM, Leisten J, Lipps SG, McKie JA, et al. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat. Calcif Tissue Int in press [doi:10.1007/s00223-002-1029-2].
33. Quinn J., Elliott J., Gillespie M., Martin T. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
34. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 25:1999;517-523.
35. Tsurukai T., Udagawa N., Matsuzaki K., Takahashi N., Suda T. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J Bone Miner Metab. 18:2000;177-184.
36. Atkins G.J., Haynes D.R., Geary S.M., Loric M., Crotti T.N., Findlay D.M. Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone. 26:2000;653-661.
37. Menaa C., Reddy S.V., Kurihara N., Maeda H., Anderson D., Cundy T., et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest. 105:2000;1833-1838.
38. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 275:2000;768-775.
39. O'Brien C.A., Lin S.C., Bellido T., Manolagas S.C. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. J Cell Biochem. 79:2000;532-541.
40. Palmqvist P., Persson E., Conaway H.H., Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappaB ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvariae. J Immunol. 169:2002;3353-3362.
41. Stein B., Kung Sutherland M. IL-6 as a drug discovery target. Drug Discov Today. 3:1998;202-213.
42. Fu Q., Jilka R.L., Manolagas S.C., O'Brien C.A. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem. 277:2002;48868-48875.
43. Li X., Pilbeam C.C., Pan L., Breyer R.M., Raisz L.G. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone. 30:2002;567-573.
44. Jimi E., Akiyama S., Tsurukai T., Okahashi N., Kobayashi K., Udagawa N., et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol. 163:1999;434-442.
45. Kinpara K., Mogi M., Kuzushima M., Togari A. Osteoclast differentiation factor in human osteosarcoma cell line. J Immunoassay. 21:2000;327-340.
46. Haynes D.R., Crotti T.N., Potter A.E., Loric M., Atkins G.J., Howie D.W., et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br. 83:2001;902-911.
47. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 275:2000;4858-4864.
48. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 191:2000;275-286.
49. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 32:2003;1-7.
50. Kimble R., Srivastava S., Ross F., Matayoshi A., Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem. 271:1996;28890-28897.
51. Sarma U., Flanagan A.M. Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood. 88:1996;2531-2540.
52. Shevde N.K., Bendixen A.C., Dienger K.M., Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A. 97:2000;7829-7834.
53. Oursler M., Pederson L., Fitzpatrick L., Riggs B., Spelburg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci U S A. 91:1994;5227-5231.
54. Mano H., Yuasa T., Kameda T., Miyzawa K., Nakamuru Y., Shiokawa M., et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun. 223:1996;637-642.
55. Oursler M.J., Landers J.P., Riggs B.L., Spelsberg T.C. Oestrogen effects on osteoblasts and osteoclasts. Ann Med. 25:1993;361-371.
56. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol. 144:1990;4226-4230.
57. Cosman F., Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev. 20:1999;418-434.
58. Gowen M. Emerging therapies for osteoporosis. Emerg Drugs. 5:2000;1-43.
59. Bodine P., Trailsmith M., Komm B. Development and characterization of a conditionally transformed adult human osteoblastic cell line. J Bone Miner Res. 11:1996;806-819.
60. Green S., Walter P., Kumar V., Krust A., Bornert J.-M., Argos P., et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 320:1986;134-143.
61. Mosselman S., Polman J., Dijkeme R. ERb: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53.
62. Sutherland M., Hui D., Rao L., Wylie J., Murray T. Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS-2 cells: association of receptor levels with alkaline phosphatase activity. Bone. 18:1996;361-369.
63. Kuestner R., Elrod R., Grant F., Hagen F., Kuijper J., Matthewes S., et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol. 46:1994;246-255.